ZENITH HEALTHCARE LIMITED |
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
| 4.31 INR | +1.17% |
|
-1.60% | -20.63% |
| 05-29 | Zenith Healthcare Limited Announces Board Resignations | CI |
| 05-29 | Zenith Healthcare Limited Reports Earnings Results for the Full Year Ended March 31, 2024 | CI |
| Sales 2022 | 226M 2.7M 213M | Sales 2023 | 132M 1.58M 125M | Capitalization | 214M 2.56M 202M |
|---|---|---|---|---|---|
| Net income 2022 | 3M 35.9K 2.83M | Net income 2023 | - 0 0 | EV / Sales 2022 | 1.62 x |
| Net cash position 2022 | 18.7M 224K 17.65M | Net cash position 2023 | 9.16M 110K 8.64M | EV / Sales 2023 | 1.55 x |
| P/E ratio 2022 |
123
x | P/E ratio 2023 |
284
x | Employees | 42 |
| Yield 2022 * |
-
| Yield 2023 |
-
| Free-Float | 65.78% |
More Fundamentals
* Assessed data
More news
| 1 day | +1.17% | ||
| 1 week | -1.60% | ||
| Current month | -2.49% | ||
| 1 month | -4.86% | ||
| 3 months | -2.05% | ||
| 6 months | -14.14% | ||
| Current year | -20.63% |
1 week
4.16
4.50
1 month
4.064.71
Current year
3.616.50
1 year
3.616.50
3 years
3.6111.60
5 years
0.7715.38
10 years
0.3815.38
| Managers | Title | Age | Since |
|---|---|---|---|
| Chief Executive Officer | 35 | 28/10/10 | |
| Chief Executive Officer | 70 | 14/11/94 | |
| Director of Finance/CFO | - | 13/05/19 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
| Chief Executive Officer | 70 | 14/11/94 | |
| Director/Board Member | 61 | 12/03/01 | |
| Director/Board Member | 57 | 31/03/03 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 26/06/24 | 4.31 | +1.17% | 24 879 |
| 25/06/24 | 4.26 | -0.23% | 54,021 |
| 24/06/24 | 4.27 | -1.16% | 36,283 |
| 21/06/24 | 4.32 | -1.59% | 54,677 |
| 20/06/24 | 4.39 | +0.23% | 50,813 |
Delayed Quote Bombay S.E., June 26, 2024 at 08:43 am
More quotes
Zenith Healthcare Limited is an India-based integrated pharmaceutical company. The Company is engaged in the manufacturing of pharmaceutical formulations in the forms of tablets, capsules, oral liquid and injectable. The Company offers contract manufacturing of all dosage forms. It is focused on various therapeutic areas, such as antibiotics and anti-infective, gastrointestinal, analgesic/anti-inflammatory, cardiovascular, respiratory, ophthalmology, bio-technical products, oncology, anti-retroviral, central nervous system, nutrition, Genito urinary system, and skin. Its products include general, such as general tablets, general capsules and general liquids, and beta-lactam, such as beta-lactam tablets, beta-lactam capsules and beta-lactam liquids. The Company exports its products to various countries, such as Cambodia, Myanmar, Papua New Guinea, Sri Lanka, Nigeria, Gambia, Zambia, Namibia, Paraguay, Bolivia, Venezuela, Guatemala, Barbados, Jamaica, Bahamas, Yemen and Turkey.
Sector
Pharmaceuticals
Calendar
08/08/2024
- Q1 2025 Earnings Release (Projected)
| 1st Jan change | Capi. | |
|---|---|---|
| -20.63% | 2.74M | |
| +20.00% | 43.29B | |
| +27.64% | 22.38B | |
| +20.14% | 15.51B | |
| +19.14% | 14.52B | |
| +55.93% | 12.93B | |
| -0.05% | 6.79B | |
| -11.39% | 6.56B | |
| +17.73% | 5.87B | |
| -8.87% | 5.73B |
- Stock Market
- Equities
- ZENITHHE6 Stock
